The store will not work correctly when cookies are disabled.
Rac-2-amino-3-(1H-imidazol-4-yl)-N-(quinolin-8-ylmethyl)propanamide
ID: ALA5284416
Max Phase: Preclinical
Molecular Formula: C16H17N5O
Molecular Weight: 295.35
Associated Items:
Names and Identifiers
Canonical SMILES: NC(Cc1c[nH]cn1)C(=O)NCc1cccc2cccnc12
Standard InChI: InChI=1S/C16H17N5O/c17-14(7-13-9-18-10-21-13)16(22)20-8-12-4-1-3-11-5-2-6-19-15(11)12/h1-6,9-10,14H,7-8,17H2,(H,18,21)(H,20,22)
Standard InChI Key: MYVWBLZGPYUKOX-UHFFFAOYSA-N
Molfile:
RDKit 2D
22 24 0 0 0 0 0 0 0 0999 V2000
3.5046 0.6212 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7905 1.0343 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0737 0.6207 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3571 1.0345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6404 0.6207 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0761 1.0345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0761 1.8620 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.7927 0.6207 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5095 1.0345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.2261 0.6207 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0112 0.8674 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.5046 0.1979 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.0325 -0.4575 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.2261 -0.2066 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.7927 -0.2066 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.0737 -0.2102 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7924 -0.6196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5046 -0.2065 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7966 -1.4441 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0827 -1.8620 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3668 -1.4563 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3570 -0.6298 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
4 3 1 0
5 4 1 0
5 6 1 0
6 7 2 0
6 8 1 0
8 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
13 12 1 0
14 10 1 0
14 13 2 0
8 15 1 0
3 16 1 0
16 17 2 0
18 1 2 0
17 18 1 0
17 19 1 0
20 19 2 0
21 20 1 0
22 21 2 0
16 22 1 0
M END
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 295.35 | Molecular Weight (Monoisotopic): 295.1433 | AlogP: 1.14 | #Rotatable Bonds: 5 |
Polar Surface Area: 96.69 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 13.06 | CX Basic pKa: 7.84 | CX LogP: 0.29 | CX LogD: -0.29 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.66 | Np Likeness Score: -0.84 |
References
1. Rahman MS, Kumari S, Esfahani SH, Nozohouri S, Jayaraman S, Kinarivala N, Kocot J, Baez A, Farris D, Abbruscato TJ, Karamyan VT, Trippier PC.. (2021) Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability., 64 (17.0): [PMID:34436882] [10.1021/acs.jmedchem.1c00759] |